Stock analysts at Craig Hallum started coverage on shares of MediWound (NASDAQ:MDWD - Get Free Report) in a research note issued to investors on Friday, MarketBeat Ratings reports. The firm set a "buy" rating and a $39.00 price target on the biopharmaceutical company's stock. Craig Hallum's target price points to a potential upside of 138.97% from the stock's current price.
Separately, HC Wainwright reiterated a "buy" rating and issued a $25.00 price objective on shares of MediWound in a report on Friday, January 10th.
Get Our Latest Analysis on MediWound
MediWound Trading Down 4.1 %
MDWD traded down $0.69 on Friday, reaching $16.32. The stock had a trading volume of 59,756 shares, compared to its average volume of 91,778. The company has a market capitalization of $176.03 million, a price-to-earnings ratio of -5.63 and a beta of 0.81. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The firm has a 50-day moving average of $18.16 and a 200-day moving average of $17.70.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of MDWD. R Squared Ltd acquired a new stake in shares of MediWound in the fourth quarter valued at about $32,000. Russell Investments Group Ltd. increased its position in MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 1,162 shares during the period. MetLife Investment Management LLC bought a new position in MediWound during the 3rd quarter worth approximately $89,000. Bank of America Corp DE lifted its position in shares of MediWound by 38.0% in the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock worth $141,000 after purchasing an additional 2,178 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after purchasing an additional 739 shares during the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Further Reading
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
